Who
Tryn Stimart
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, AbCellera Biologics.
In numbers
- Trades disclosed
- 15
- Buys
- 1
- Sells
- 1
- Bought
- $10K
- Sold
- $25.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 29 Oct 2020
- Last trade
- 1 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jan 2026filed 5 Jan 2026 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —539,265 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —539,265 at $0.00 | filing |
| 1 Jan 2025filed 3 Jan 2025 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —832,033 at $0.00 | filing |
| 14 Jan 2024filed 16 Jan 2024 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —616,333 at $0.00 | filing |
| 1 Dec 2022filed 5 Dec 2022 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —346,901 at $0.00 | filing |
| 7 Dec 2021filed 9 Dec 2021 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —270,680 at $0.00 | filing |
| 9 Jun 2021filed 10 Jun 2021 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Sold | $25.5M1,000,000 at $25.50 | filing |
| 7 Jun 2021filed 9 Jun 2021 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $240K750,000 at $0.32 | filing |
| 7 Jun 2021filed 9 Jun 2021 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $575K250,000 at $2.30 | filing |
| 7 Jun 2021filed 9 Jun 2021 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —750,000 at $0.00 | filing |
| 7 Jun 2021filed 9 Jun 2021 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —250,000 at $0.00 | filing |
| 15 Dec 2020filed 17 Dec 2020 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Bought | $5,000250 at $20.00 | filing |
| 15 Dec 2020filed 17 Dec 2020 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Bought | $5,000250 at $20.00 | filing |
| 10 Dec 2020filed 17 Dec 2020 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,800 at $0.00 | filing |
| 29 Oct 2020filed 17 Dec 2020 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —850,000 at $0.00 | filing |
News
AbCellera Biologics (NASDAQ:ABCL) Research Coverage Started at UBS GroupABCL · themarketsdaily.com · 15 Oct 2026Head to Head Review: Surrozen (NASDAQ:SRZN) vs. AbCellera Biologics (NASDAQ:ABCL)ABCL · tickerreport.com · 14 Oct 2026Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & AbCellera Biologics (NASDAQ:ABCL)ABCL · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Tryn Stimart; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.